亞輝龍(688575.SH):新型冠狀病毒抗原檢測試劑盒獲得日本PMDA認證指定供應
格隆匯2月10日丨亞輝龍(688575.SH)公佈,公司的日本合作伙伴株式會社醫學生物學研究所的新型冠狀病毒抗原檢測試劑盒於北京時間2022年2月10日取得了由日本PMDA簽發的《體外診斷產品生產銷售許可書》(即日本PMDA認證),本次認證的詳細信息也已於同日在日本厚生勞動省官方網站公示。公司作為MBL該新型冠狀病毒抗原檢測試劑盒的指定生產商,本產品獲得日本PMDA認證後,將可在日本地區銷售,可用於醫用檢測及居家自測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.